The Genetic Renal Panel is a custom next-generation targeted sequencing panel that screens 12 genes for genetic disease-drivers and risk-factors associated with thrombotic microangiopathies (TMAs) and C3 Glomerulopathy (see background for additional information).
The MORL offers the Genetic Renal Panel which is:
- Comprehensive – tests all genes known to be associated with a wide-array of TMAs and complement-mediated diseases
- Easy – patient provides one blood sample
- Convenient – blood draws are easily accessible at a patient’s local doctor’s office
- Thorough – results are discussed at a multidisciplinary meeting in the context of your patient’s phenotype, other testing ordered and current research
- Accurate – 99% diagnostic specificity
- Pinpointed diagnosis – offers guidance for treatment, prognosis for transplant and genetic counseling
An up-to-date custom targeted genomic enrichment and massively parallel sequencing panel as well as Multiplex Ligation-dependent Probe Amplification (MLPA) makeup the Genetic Renal Panel test.
Genetic Renal Panel has a diagnostic sensitivity and specificity that is greater than 99%.
Results are discussed at a multidisciplinary Renal Group meeting.
Results are sent in approximately 3 weeks.
8 - 10 cc. whole blood in lavender (EDTA) top tubes OR 10 μg DNA; minimum concentration: 50 ng/μl (A260/A280 1.8-2) resuspended in 0.1mM EDTA (10mM Tris HC1, 0.1mM EDTA, pH 8, Teknova Cat#T0220)
Cost & CPT Codes:
See the MORL testing menu
Genetic Testing for renal disease answers many important questions pertaining to patient care. The Genetic Renal Panel provides information on recurrence chance, prognosis, and best methods of treatment.